Moderna and Mitsubishi Tanabe Pharma ink agreement to promote Moderna’s mRNA respiratory vaccine portfolio in Japan
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
India boasts the largest livestock population, with 536 million livestock and 851 million poultry
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Cipla had earlier invested € 15 million in Ethris in 2022
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Subscribe To Our Newsletter & Stay Updated